{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T17:42:53Z","timestamp":1781890973708,"version":"3.54.5"},"reference-count":23,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T00:00:00Z","timestamp":1743206400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Farmacia Hospitalaria"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.farma.2025.03.016","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T01:32:48Z","timestamp":1758591168000},"page":"T354-T358","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["[Translated article] Influence of SARS-CoV-2 infection on the use of ceftazidime-avibactam in the critical patient"],"prefix":"10.1016","volume":"49","author":[{"given":"F\u00e1tima","family":"Mayo Olveira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Manuel","family":"Caro Teller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Dolores","family":"Canales Siguero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Ortiz P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda del Carmen","family":"Jim\u00e9nez Le\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Miguel","family":"Ferrari Piquero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.farma.2025.03.016_bb0005","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jiph.2016.08.007","article-title":"Antibiotic resistance","volume":"10","author":"Frieri","year":"2017","journal-title":"J Infect Public Health"},{"issue":"1","key":"10.1016\/j.farma.2025.03.016_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/mbo3.1260","article-title":"Impact of antibiotics on the human microbiome and consequences for host health","volume":"11","author":"Patangia","year":"2022","journal-title":"Microbiologyopen"},{"issue":"10325","key":"10.1016\/j.farma.2025.03.016_bb0015","doi-asserted-by":"crossref","first-page":"P629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.farma.2025.03.016_bb0020","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jgar.2019.12.009","article-title":"Resistance to ceftazidime\u2013avibactam and underlying mechanisms","volume":"22","author":"Wang","year":"2020","journal-title":"J Glob Antimicrob Resist."},{"issue":"2","key":"10.1016\/j.farma.2025.03.016_bb0025","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/cid\/ciw243","article-title":"Ceftazidime\/avibactam and ceftolozane\/tazobactam: second-generation \u03b2-lactam\/\u03b2-lactamase inhibitor combinations","volume":"63","author":"Van Duin","year":"2016","journal-title":"Clin Infect Dis."},{"issue":"Supl 2","key":"10.1016\/j.farma.2025.03.016_bb0030","first-page":"11","article-title":"Espectro y actividad in vitro de ceftazidima\/avibactam","volume":"35","author":"Oliver","year":"2017","journal-title":"Enferm Infecc Microbiol Clin."},{"key":"10.1016\/j.farma.2025.03.016_bb0035","author":"Ministerio de Sanidad de Espa\u00f1a [Internet]"},{"issue":"1","key":"10.1016\/j.farma.2025.03.016_bb0040","article-title":"Use of ceftazidime-avibactam in the treatment of clinical syndromes with limited treatment options: a retrospective study","volume":"15","author":"Radha","year":"2023","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.farma.2025.03.016_bb0045","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3390\/antibiotics12010045","article-title":"Increasing consumption of antibiotics during the COVID-19 pandemic: implications for patient health and emerging anti-microbial resistance","volume":"12","author":"Malik","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.farma.2025.03.016_bb0050","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/j.cmi.2020.07.016","article-title":"Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis","volume":"26","author":"Langford","year":"2020","journal-title":"Clin Microbiol Infect."},{"issue":"6 Pt 1","key":"10.1016\/j.farma.2025.03.016_bb0055","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.jmii.2022.09.006","article-title":"Coronavirus disease 2019 (COVID-19) associated bacterial coinfection: incidence, diagnosis and treatment","volume":"55","author":"Wu","year":"2022","journal-title":"J Microbiol Immunol Infect."},{"key":"10.1016\/j.farma.2025.03.016_bb0060","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s13054-015-1035-1","article-title":"Likelihood of infection in patients with presumed sepsis at the time of intensive care unit admission: a cohort study","volume":"19","author":"Klein Klouwenberg","year":"2015","journal-title":"Crit Care"},{"issue":"4","key":"10.1016\/j.farma.2025.03.016_bb0065","first-page":"654","article-title":"Pathologic difference between sepsis and bloodstream infections","volume":"3","author":"Huerta","year":"2019","journal-title":"J Lab Med."},{"issue":"4","key":"10.1016\/j.farma.2025.03.016_bb0070","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.eimc.2020.11.003","article-title":"Bacterial\/fungal infection in hospitalized patients with COVID-19 in a tertiary hospital in the Community of Castilla y Le\u00f3n, Spain","volume":"40","author":"Nebreda-Mayoral","year":"2020","journal-title":"Enferm Infecc Microbiol Clin (Engl Ed.)"},{"key":"10.1016\/j.farma.2025.03.016_bb0075","article-title":"Utilizaci\u00f3n de antibi\u00f3ticos restringidos en la pr\u00e1ctica cl\u00ednica: ceftolozano\/tazobactam, ceftazidima\/avibactam, ceftarolina y dalbavancina","author":"Hern\u00e1ndez-Terciado","year":"2022","journal-title":"Rev. OFIL"},{"issue":"369","key":"10.1016\/j.farma.2025.03.016_bb0080","article-title":"Features of 20\u202f133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study","volume":"22","author":"Docherty","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.farma.2025.03.016_bb0085","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.cmi.2020.07.041","article-title":"Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study","volume":"27","author":"Garcia-Vidal","year":"2021","journal-title":"Clin Microbiol Infect."},{"issue":"1","key":"10.1016\/j.farma.2025.03.016_bb0090","first-page":"270","article-title":"COVID-19 length of hospital stay: a systematic review and data synthesis","volume":"18","author":"Rees","year":"2020","journal-title":"BMC"},{"issue":"12","key":"10.1016\/j.farma.2025.03.016_bb0095","article-title":"Dysregulated inflammation during obesity: driving disease severity in influenza virus and SARS-CoV-2 infections","volume":"28","author":"Hulme","year":"2021","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.farma.2025.03.016_bb0100","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41574-020-00435-4","article-title":"COVID-19 and diabetes mellitus: from pathophysiology to clinical management","volume":"17","author":"Lim","year":"2021","journal-title":"Nat Rev Endocrinol."},{"issue":"3","key":"10.1016\/j.farma.2025.03.016_bb0105","article-title":"Infecciones bacterianas asociadas a la COVID-19 en pacientes de una unidad de cuidados intensivos","volume":"49","author":"Aguilera-Calzadilla","year":"2020","journal-title":"Rev Cuba Med Mil."},{"issue":"Supl 1","key":"10.1016\/j.farma.2025.03.016_bb0110","first-page":"S64","article-title":"Terapia antimicrobiana personalizada en pacientes cr\u00edticos y en edad avanzada","volume":"45","author":"Grau","year":"2021","journal-title":"Farm Hosp."},{"issue":"8","key":"10.1016\/j.farma.2025.03.016_bb0115","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.3390\/antibiotics11081007","article-title":"Ceftazidime\/avibactam in ventilator-associated pneumonia due to difficult-to-treat non-fermenter gram-negative bacteria in COVID-19 patients: a case series and review of the literature","volume":"11","author":"Burastero","year":"2022","journal-title":"Antibiotics (Basel)"}],"container-title":["Farmacia Hospitalaria"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634325000418?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634325000418?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T22:44:00Z","timestamp":1762209840000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130634325000418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1130634325000418"],"URL":"https:\/\/doi.org\/10.1016\/j.farma.2025.03.016","relation":{},"ISSN":["1130-6343"],"issn-type":[{"value":"1130-6343","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"[Translated article] Influence of SARS-CoV-2 infection on the use of ceftazidime-avibactam in the critical patient","name":"articletitle","label":"Article Title"},{"value":"Farmacia Hospitalaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2025.03.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2024.10.018","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Sociedad Espa\u00f1ola de Farmacia Hospitalaria (S.E.F.H). Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}